Hyperthermic regional perfusion for melanoma and sarcoma of the limbs

Current Problems in Surgery

Volumn 36, Issue 11, 1999, Pages 851-905

  Fraker, Douglas L ^a   Rhoads, Jonathan E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748968131     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing extracorporeal circuit. Ann Surg 1958;148:616-32.
2. Krementz ET. Carter RD, Sutherland CM, Muchmore JH, Ryan RF, Creech O Jr. Regional chemotherapy for melanoma: a 35 year experience. Ann Surg 1994:220: 520-35.
3. Rigel DS. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis and treatment. CA Cancer J Clin 1996;46:195-8.
4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. Cancer J Clin 1999:49:8-31.
5. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors, Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Co; 1997. p 1947-97.
6. Cumberlin R. DeMoss E, Lassus M, Friedman M. Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 1985:3:1022-31.
7. McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975; 182: 316-24.
8. Franklin HR, Koops HS. Oldhoff J. et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988:6:701-8.
9. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16:2906-12.
10. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991;9:2091-4.
11. 1. Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma. Ann Surg 1952:136:905-11.
12. Tumbull A, Shah J, Fortner J. Recurrent melanoma of an extremity treated by major amputation. Arch Surg 1973;106:496-8.
13. Jaques DR Coit DG, Brennan MF. Major amputation for advanced malignant melanoma. Surg Gynecol Obstet 1989; 169:1-6.
14. Kourtesis GJ, McCarthy WH. Milton GW. Major amputations for melanoma. Aust NZJSurg 1983:53:241-4.
15. Vrouenraets BC. Nieweg OE. Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-28.
16. Coit DG. Isolation limb perfusion for melanoma: current trends and future directions. Melanoma Research 1994;4(suppl):57-60.
17. Fraker DL. Coit DG. Isolated perfusion of extremity tumors. In: Lotze MT, Rubin IT, editors. Regional therapy of advanced cancer. Philadelphia: Lippincott-Raven; 1997. p 333-49.
18. Luck JM. Action of p-{Di(2-chloroethyl)}-amino-Lphenylalanine on HardingPassey mouse melanoma. Science 1955:123:984-5.
19. Martijn H, Oldhoff J, Koops HS. Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities. J Surg Oncol 1982;20:9-13.
20. Thompson JF, Gianoutsos MR Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992:16:227-33.
21. Wieberdink J. Benckhuysen C, Braat RR van Slooten EA, Olthuis GAA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982:18:905-10.
22. Boddie AW. Briele H, Krementz E, et al. A phase I study of melphalan in 40°C isolated limb perfusion using packed red blood cells and lactated ringers perfusate [abstract], Proc ASCO 1992;11:351.
23. Martijn H, Koops HS, Milton GW, et al. Comparison of two methods of treating primary malignant melanomas Clark IV and V thickness 1.5 mm and greater, localized on the extremities. Cancer 1986:57:1923-30.
24. Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. Arch Surg 1990:25:317-21.
25. Ghussen F. Kruger I. Groth W. Stutzer H. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988:61:654-9.
26. Ghussen F, Nagel K, Groth W, Muller JM, Stutzer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984:200:764-8.
27. Rosin RD, Westbury G. Isolated limb perfusion for malignant melanoma. Practitioner 1980:224:1031-6.
28. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent lirnb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989:63:2551-61.
29. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985; 150:32-5.
30. Jonsson PE. Hafstrom L, Hugander A. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. In: Recent results in cancer research. Vol 86. Berlin: Springer-Verlag; 1983. p 277-82.
31. Lejeune FI. Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in-transit métastases after hyperthermic isolation perfusion of the limbs with melphalan. In: Recent results in cancer research. Vol. 86. Berlin: SpringerVerlag; 1983. p 268-76.
32. Skene AI, Bulman AS, Williams TF, Thomas JM, Westbury G. Hyperthermic isolated limb perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990;77:765-7.
33. Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985:55:2638-44.
34. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR, Hart AAM. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115:39-45.
35. Bulman A, Jamieson CVV. Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980:67:660-2.
36. Kroon BR, van Geel AN, Benckhuijsen C, Wieberdink J. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res 1987:7:441-2.
37. Kroon BBR. Klaase JM, van Geel BN, Eggermont ANN, Franklin HR, van Dongen JA. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993;29A:325-8.
38. Cavalière R, Ciogatto EC, Giovanelli BC, et al. Selective heat sensitivity of cancer cells. Cancer 1967;20:1351-81.
39. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremity. Surg Gynecol Obstet 1969:129:305-8.
40. Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Andersen RF. Hyperthermic perfusion with chemotherapy for cancers of the extremity. Surg Gynecol Obstet 1975;140:339-48.
41. Klaase J, Kroon BBR, Eggermont AMM, et al. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995:31:58-63.
42. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994:178:564-72.
43. Sutherland CM, Mather Fl, Krementz ET. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 1987:164:111-8.
44. Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience. Ann Surg 1972;175:900-17.
45. Scott RN. Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, editors. Progress in regional cancer therapy. Berlin: Springer-Verlag: 1990. p 195-200.
46. Benckhuijsen C, Kroon BBR, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J SurgOncol 19888;14:157-63.
47. Lejeune FJ, Ghanem GE. A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 1987:47:639-43.
48. Briele HA, Djuric M, Jung DT, Mortell T. Patel MK, Das Gupta TK. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 1985: 45:1885-9.
49. Benckhuijsen C, Varossieau FJ. Hart AAM. Wieberdink J, Noordhoek J. Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 1986;237:583-8.
50. Scott RN. Blackie R, Kerr DJ, et al. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992:28:1811-3.
51. Coit DG, Bajorin DF. Menendez-Botet C, et al. A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma [abstract]. Proc ASCO 1991:10:294.
52. Hoekstra HJ, Koops HS, deVries LGE, van Weerden TW, Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993;72:1224-9.
53. Aigner K. Hild P, Henneking K, Paul E, Hundeiker M. Regional perfusion with cisplatinum and dacarbazine. In: Recent results in cancer research. Vol 86. Berlin: Springer-Verlag; 1983. p 239-45.
54. Vaglini M, Belli F, Marolda R, Prada A, Santinami M, Cascinelli N. Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol 1987:13:127-9.
55. Shiu MH, Knapper WH. Fortner JG. et al. Regional isolated limb perfusion of melanoma intransit métastases using mechlorethamine (nitrogen mustard). J Clin Oncol 1986:4:1819-26.
56. Fletcher WS. Pommier RF. Woltering EA, Mueller CR, Ash KO, Small KA. Pharmacokinetics and results of dose escalation in cisplatin hyperthermic isolation limb perfusion. Ann Surg Oncol 1994:1:236-43.
57. Guchelaar HJ, Hoekstra HJ. deVries EGE, Uges DRA, Oosterhuis JW, Koops HS. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer 1992:65:898-902.
58. Carswell EA, Old LJ. Kassel RL, Green S, Fiore N, Williamson B. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sei USA 1975:72:3666-70.
59. Fraker DL, Alexander HR, Pass HI. Biologic therapy of tumor necrosis factor: clinical applications by systemic and regional administration. In: DeVita V, Hellman S, Rosenberg SA, editors. Bioloqic therapy of cancer. 2nd ed. Philadelphia: Lippincott; 1995. p 329-46.
60. Lejeune FI. High dose recombinant tumour necrosis factor (rTNFi-1) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 1995;31:1009-16.
61. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: De Vita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott; 1994. p 179-92.
62. Leinard D, Lejeune F, Delmotte J, et al. High doses of rTNF in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
63. Posner MC. Lienard D, Lejeune FJ. Rosenfelder D, Kirkwood J. Hyperthermic iso-lated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995; 1:274-80.
64. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for tumor necrosis factor and their regulation by gamma-interferon. Nature 1985:318:665-7.
65. Lienard D, Lejeune F, Ewalenko I. In transit métastases of malignant melanoma treated by high dose rTNF in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
66. Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin SurgOncol 1998:14:202-9.
67. Fraker DL, Alexander HR. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects: the NCI results. Melanoma Res 1994;4(suppl):27-9.
68. Fraker DL, Alexander HR, Bartlett DL, Rosenberg SA. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-an initial report [abstract]. Proceedings of the Society of Surgical Oncology 1996:49:6.
69. Asher A, Mule JJ, Reichert CM, Shiloni A, Rosenberg SA. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987:138:963-74.
70. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb persuion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol 1996:14:479-89.
71. Folli S, Pelegrin A, Chalandon Y, et al. Tumor-necrosis factor can enhance radioantibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993:53:829-36.
72. Vargas HI, McFarlane M, Vargas MP, et al. Effects of intravascular (IV) tumor necrosis factor (TNF) on vascular permeability (VP) and blood flow (BF) in tumor and normal tissue [abstract]. Proceedings of the American Association of Cancer Research 1996:37:486.
73. Bartlett DL, Ma G. Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997:80:2084-90.
74. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sei Am 1995; 1:122-30.
75. Sorkin P, Abu-Abid S, Lev D, et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1995:130:1079-84.
76. Thorn AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma and melphalan. J Clin Oncol 1995:13:264-73.
77. Hill S, Fawcett J, Sheidon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993:80:995-7.
78. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb can-cer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon. and melphalan. Cancer 1994;73:483-92.
79. Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997. p. 1738-88.
80. Williard WG. Collin C. Casper ES, Hajdu SI, Brennan MF. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet 1992:175:389-96.
81. Williard WC. Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992:215:269-75.
82. Prewitt TW, Alexander HR, Sindelar WF. Hemipelvectomy for soft tissue sarcoma: clinical results in fifty-three patients. Surg Oncol 1995:4:261-9.
83. Krementz ET. Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977:185:555-64.
84. Stehlin JS, delpolyi PD, Giovanella BC, Gutierrez AE. Anderson RF. Soft tissue sarcomas of the extremity. Am J Surg 1975; 130:643-6.
85. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision,and radiation therapy. Surg Gynecol Obstet 1986:162:149-52.
86. Moseley HS. An evaluation of two methods of limb salvage in extremity soft tissue sarcomas. Arch Surg 1992; 127:1169-74.
87. Hoekstra HJ, Koops HS, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987:60:1703-7.
88. Klaase JM. Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE. Wieberdink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremity. Cancer 1989:64:616-21.
89. Seyedi JV. Lienard D. Bourgeois P, Lejeune F. Treatment of advanced angiosarcomas of the limbs by isolation perfusion. Regional Cancer Treatment 1990:3: 98-102.
90. DiFillippo F, Carlini S. Cavalière F, et al. The role of hyperthermic perfusion in thé treatment of tumors of the extremities. In: Bicher HI, editor. Consensus on hyperthermia for the 1990s. New York: Plenum Press; 1990. p 343-50.
91. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140-6.
92. Eggermont AMM. Koops HS. Lienard D. et al. Isolated limb perfusion with high dose tumor necrosis factor-a in combination with interferon-y and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996:14:2653-65.
93. Eggermont AMM, Koops HS, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996:244:756-65.
94. Gutman M, Inbar M, Lev-Shluch D. et al. High dose tumor necrosis factor-alpha and melpalan administered via limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997:79:1129-37.
95. Fraker DL, Alexander HR, Ross M, Tyler D, Bartlett D, Bauer T. A phase II trial of isolated limb perfusion with high dose tumor necrosis factor and melphalan for unresectable extremity sarcomas [abstract]. Society of Surgical Oncology Cancer Symposium 1999:52:22.
96. Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995:22:1242-8.
97. Vargas HI, Alexander HR, Andrich MP, et al. Assessment of perfusate leak during isolated limb perfusion (ILP) with tumor necrosis factor (TNF)[abstract]. Society of Surgical Oncology Cancer Symposium 1996:49:67.
98. Taber SW, Polk HC Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997:4:440-5.
99. van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989:63:1092-6.
100. Olieman AFT, Koops HS, Geertzen JHB, Kingma H, Hoekstra HJ, Oldhoff J. Functional morbidity of hyperthemic isolated regional perfusion of the extremities. Ann Surg Oncol 1994:3:382-8.
101. Thompson JF, Eksborg S, Kam PC, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. Melanoma Res 1996:6:267-71.
102. Vrouenraets BC, Klaase JM. Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998:14:224-31.
103. Drory VE. Lev D, Groozman GB, Gutmann M. Klausner JM. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurolog Sei 1998; 158:1-4.
104. Klicks RJ, Vrouenraets BC, Nieweg OE, Kroon BB. Vascular complications of isolated limb perfusion. Eur J Surg Oncol 1998:24:288-91.
105. Hoekstra HJ, Naujocks T, Koops HS, et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results. Regional Cancer Treatment 1992:4:301-4.